Abstract:BACKGROUND:Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer.METHODS:Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible. The patients underwent thoracic radiotherapy (45 Gy, 1.5 Gy bid, 30 fractions for 3 weeks) delivered concurrently with etoposide (100 mg/m2 iv, days 1-3) and cisplatin dose escalating from the two levels ( 70 mg/m2 and 75 mg/m2 on d1). The primary endpoints were hematologic toxicities during treatment. The secondary endpoints were non-hematologic toxicities, overall survival (OS) and progression-free survival (PFS). According to Common Terminology Criteria for Adverse Events 4.0 (CTC-AE 4.0), maximum tolerant dosage (MTD) was defined as the highest safely tolerated dose at which no more than one patient out of six experiences dose-limiting toxicity (Grades 4 hematologic), with the next higher dose having at least two out of six patients experience dose-limiting toxicity.RESULTS:From January 2013 to August 2016, 20 patients were enrolled in this study. The median age was 49.5 (30-68). After the first 6 patients were enrolled in Arm 1 (70 mg/m2 on d1), one patient had Grade 4 neutropenia. Another 14 patients were enrolled in Arm 2 (75 mg/m2 on d1), one patient had Grade 4 neutropenia. The MTD was determined to be etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). 4 patients had ≥Grade 3 neutropenia and 1 patients had ≥Grade 3 acute esophagitis in Arm 1. 10 patients had ≥Grade 3 neutropenia and no patient had ≥Grade 3 acute esophagitis in Arm 2. All patients with a median follow-up time was 9.0 months, median OS and PFS were not achieved, 1-year OS and PFS were 91% and 61%, respectively.CONCLUSIONS:The MTD of RT with concurrent chemotherapy of EP regimen for patients with LS-SCLC was etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). .

Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.

Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.

Cisplatin Plus Etoposide Versus Other Platin-Based Regimens For Patients With Extensive Small-Cell Lung Cancer: A Systematic Review And Meta-Analysis Of Randomised, Controlled Trials

Preliminary Results of Randomized Phase II Study of Etoposide Plus Lobaplatin or Etoposide Plus Cisplatin with Concurrent Thoracic Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer.

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Etoposide plus lobaplatin versus etoposide plus cisplatin for patients with extensive stage small cell lung cancer:A Meta -analysis

A Meta Analysis of Cisplatin Combined with Irinotecan or Etoposide in the Treatment of Extensive-Disease Small Cell Lung Cancer

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

Navelbine-ifosfamide-cisplatin Versus Etoposide-Cisplatin As the First-Line Treatment of Advanced Combined Small-Cell Lung Cancer:Retrospective Analysis of 167 Cases

Vinorelbine based combination chemotherapy in advanced non-small cell lung cancer

Randomized Phase III Trial of Amrubicin/cisplatin Versus Etoposide/cisplatin As First-Line Treatment for Extensive Small-Cell Lung Cancer.

A Randomized Controlled Study of Chemotherapy: Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment of Extensive-stage Small Cell Lung Cancer in Elderly Patients

Randomized Controlled Trial of Lobaplatin Plus Etoposide Vs. Cisplatin Plus Etoposide As First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer.

Irinotecan/cisplatin Versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review

Efficacy and safety of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer

Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation with Concurrent Twice-daily Radiotherapy for Patients with Limited-stage Small Cell Lung Cancer

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Efficacy and Safety of PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Comparative Study of Iobaplatin and Cisplatin Combined with Etoposide for Advanced Small Cell Lung Cancer

A Randomized, Multicenter Phase III Study of Lobaplatin/etoposide Versus Cisplatin/etoposide As First-Line Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer and Circulating Tumor Cells (ctcs) As an Exploratory Biomarker.